DDInter1230 DDInter927
Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6157] The effects of this drug may be observed as early as 1 week after beginning therapy.[A178144,L6160] In addition to its beneficial effects in depression, mirtazapine has been reported to be efficacious in the off-label management of various other conditions. It may improve the symptoms of neurological disorders, reverse weight loss caused by medical conditions, improve sleep, and prevent nausea and vomiting after surgery.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Mirtazapine {u} (Compound) resembles {v} (Compound) Mianserin
Mirtazapine {u} (Compound) resembles {v} (Compound) Chlorcyclizine
Mirtazapine {u} (Compound) binds {v} (Gene) HTR2C
Mirtazapine {u} (Compound) upregulates {v} (Gene) AGR2
Mirtazapine {u} (Compound) downregulates {v} (Gene) KIF20A
Mirtazapine {u} (Compound) causes {v} (Side Effect) Cardiomegaly
Mirtazapine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Mirtazapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lapatinib
Mirtazapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Mirtazapine {u} may lead to a major life threatening interaction when taken with {v} Bupropion
Mirtazapine (Compound) resembles Mianserin (Compound)
Mirtazapine (Compound) resembles Chlorcyclizine (Compound)
Mirtazapine (Compound) binds HTR2C (Gene)
Mirtazapine (Compound) upregulates AGR2 (Gene)
Mirtazapine (Compound) downregulates KIF20A (Gene)
Mirtazapine (Compound) causes Cardiomegaly (Side Effect)
Mirtazapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine
Mirtazapine may lead to a major life threatening interaction when taken with Bupropion